Please assess the completion status of the following clinical trial:

Trial Title: A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;~* Presence of bone metastatic disease as assessed by at least two lesions on whole body metastable technetium-methylene diphosphonate (99mTc-MDP) bone scintigraphy;~* Throughout the study, ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone (LHRH) analogue or prior bilateral orchiectomy (medical or surgical castration);~* Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening;~* Progressive disease on androgen deprivation therapy at screening defined as a minimum of two sequentially rising prostate-specific antigen (PSA) values (PSA1 \< PSA2 \< PSA3);~* The screening PSA (PSA3) must be ≥ 2 μg/L (≥ 2 ng/mL).~Exclusion Criteria:~* Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the CRPC setting for the treatment of prostate cancer or participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless treatment was placebo);~* Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy) within 4 weeks before enrollment;~* Initiation of new treatment with denosumab, bisphosphonates, or systemic corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;~* Use of an investigational agent within 4 weeks before the screening visit;~* Radiation therapy to bone within 4 weeks before enrollment;~* Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;~* Screening 99mTc-MDP bone scintigraphy showing a superscan;~* Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;~* Current or previously treated brain metastasis or active leptomeningeal disease;~* History of seizure any time in the past for any reason or any condition that may predispose to seizures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide monotherapy (Type: EXPERIMENTAL): Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).